1. Home
  2. PLSE vs MPLT Comparison

PLSE vs MPLT Comparison

Compare PLSE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$41.70

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$12.29

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
MPLT
Founded
2014
2018
Country
United States
United States
Employees
N/A
133
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PLSE
MPLT
Price
$41.70
$12.29
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$22.00
$32.67
AVG Volume (30 Days)
369.3K
1.4M
Earning Date
05-07-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$9.10
52 Week High
$45.90
$40.43

Technical Indicators

Market Signals
Indicator
PLSE
MPLT
Relative Strength Index (RSI) 73.70 28.72
Support Level $24.27 $11.56
Resistance Level N/A $20.73
Average True Range (ATR) 3.05 2.03
MACD 0.75 -1.11
Stochastic Oscillator 70.84 11.12

Price Performance

Historical Comparison
PLSE
MPLT

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: